{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:54:51Z","timestamp":1774918491244,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jsat.2011.09.007","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T20:54:56Z","timestamp":1319835296000},"page":"438-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States"],"prefix":"10.1016","volume":"42","author":[{"given":"Edmund J.","family":"Bini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Lawrence S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Calsyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Alderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathlene","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"McAuliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2011.09.007_bb0005","doi-asserted-by":"crossref","first-page":"838","DOI":"10.7326\/0003-4819-110-10-838","article-title":"Fulminant hepatitis A in intravenous drug users with chronic liver disease","volume":"110","author":"Akriviadis","year":"1989","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2011.09.007_bb0010","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/S0264-410X(03)00139-7","article-title":"HAV infection in chronic liver disease: A rationale for vaccination","volume":"21","author":"Almasio","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jsat.2011.09.007_bb0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2011.09.007_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/003335490712200404","article-title":"Health services for HIV\/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs","volume":"122","author":"Brown","year":"2007","journal-title":"Public Health Reports"},{"key":"10.1016\/j.jsat.2011.09.007_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jsat.2006.02.006","article-title":"Characteristics of substance abuse treatment programs providing services for HIV\/AIDS, hepatitis C virus infection, and sexually transmitted infections: The National Drug Abuse Treatment Clinical Trials Network","volume":"30","author":"Brown","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2011.09.007_bb0030","first-page":"1","article-title":"Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","journal-title":"Morbidity & Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2011.09.007_bb0035","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"Morbidity & Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2011.09.007_bb0040","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"Morbidity & Mortality Weekly Report"},{"issue":"Suppl","key":"10.1016\/j.jsat.2011.09.007_bb0045","first-page":"S17","article-title":"The importance and benefits of hepatitis A prevention in chronic liver disease patients","volume":"19","author":"Cooksley","year":"2004","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMcp031540","article-title":"Prevention of hepatitis A with the hepatitis A vaccine","volume":"350","author":"Craig","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2011.09.007_bb0055","first-page":"213","article-title":"Guidelines for the control of hepatitis A virus infection","volume":"4","author":"Crowcroft","year":"2001","journal-title":"Communicable Disease and Public Health"},{"key":"10.1016\/j.jsat.2011.09.007_bb0060","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/00004836-200411003-00008","article-title":"Global epidemiology of hepatitis B virus","volume":"38","author":"Custer","year":"2004","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2","article-title":"A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma","volume":"75","author":"Donato","year":"1998","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.jsat.2011.09.007_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.drugpo.2005.02.008","article-title":"Effectiveness of drug dependence treatment in HIV prevention","volume":"16","author":"Farrell","year":"2005","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2011.09.007_bb0075","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.20383","article-title":"Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B","volume":"40","author":"Garfein","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11901-006-0003-2","article-title":"Vaccination against hepatitis A in patients with chronic liver disease","volume":"5","author":"Gaslightwala","year":"2006","journal-title":"Current Hepatitis Reports"},{"key":"10.1016\/j.jsat.2011.09.007_bb0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0091270003258669","article-title":"Global burden of disease (GBD) for hepatitis C","volume":"44","year":"2004","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0090","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/339192","article-title":"Incidence and risk factors for acute hepatitis B in the United States, 1982\u20131998: Implications for vaccination programs","volume":"185","author":"Goldstein","year":"2002","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 10A","key":"10.1016\/j.jsat.2011.09.007_bb0095","doi-asserted-by":"crossref","first-page":"100S","DOI":"10.1016\/j.amjmed.2005.07.028","article-title":"Public health perspective on vaccine-preventable hepatitis: Integrating hepatitis A and B vaccines into public health settings","volume":"118","author":"Hershey","year":"2005","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.jsat.2011.09.007_bb0100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0740-5472(03)00130-2","article-title":"Overview of 5-year followup outcomes in the Drug Abuse Treatment Outcome Studies (DATOS)","volume":"25","author":"Hubbard","year":"2003","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2011.09.007_bb0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/clinids\/10.2.377","article-title":"Role of drug abuse treatment in limiting the spread of AIDS","volume":"10","author":"Hubbard","year":"1988","journal-title":"Reviews of Infectious Diseases"},{"key":"10.1016\/j.jsat.2011.09.007_bb0110","series-title":"Clinical Trials Network summary & comparison report. NTCS Report No. 10","author":"Institute for Behavioral Research","year":"2005"},{"issue":"Suppl 10A","key":"10.1016\/j.jsat.2011.09.007_bb0115","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/j.amjmed.2005.07.013","article-title":"Acute hepatitis A and B in patients with chronic liver disease: Prevention through vaccination","volume":"118","author":"Keeffe","year":"2005","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.jsat.2011.09.007_bb0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jmv.10407","article-title":"Hepatitis C virus infection among noninjecting drug users in New York City","volume":"70","author":"Koblin","year":"2003","journal-title":"Journal of Medical Virology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00004836-200107000-00006","article-title":"Risks associated with hepatitis A and hepatitis B in patients with hepatitis C","volume":"33","author":"Koff","year":"2001","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0130","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(03)15108-2","article-title":"Viral hepatitis B","volume":"362","author":"Lai","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2011.09.007_bb0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0140","first-page":"97","article-title":"Drug abuse treatment as AIDS prevention","volume":"113","author":"Metzger","year":"1998","journal-title":"Public Health Reports"},{"key":"10.1016\/j.jsat.2011.09.007_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2105\/AJPH.89.1.14","article-title":"Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994","volume":"89","author":"McQuillan","year":"1999","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2011.09.007_bb0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2105\/AJPH.92.3.385","article-title":"Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities","volume":"92","author":"Murrill","year":"2002","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2011.09.007_bb0155","first-page":"S3","article-title":"National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002\u2014June 10\u201312, 2002","volume":"36","author":"National Institutes of Health","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1017\/S0950268801006185","article-title":"An outbreak of hepatitis A amongst injecting drug users","volume":"127","author":"O'Donovan","year":"2001","journal-title":"Epidemiology and Infection"},{"key":"10.1016\/j.jsat.2011.09.007_bb0165","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1056\/NEJMcp041507","article-title":"Clinical practice: Prevention of hepatitis B with the hepatitis B vaccine","volume":"351","author":"Poland","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 10A","key":"10.1016\/j.jsat.2011.09.007_bb0170","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1016\/j.amjmed.2005.07.029","article-title":"Evaluating existing recommendations for hepatitis A and B vaccination","volume":"118","author":"Poland","year":"2005","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.jsat.2011.09.007_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1086\/375566","article-title":"Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy","volume":"37","author":"Quaglio","year":"2003","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2011.09.007_bb0180","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.vaccine.2005.12.045","article-title":"Hepatitis vaccination among drug users","volume":"24","author":"Quaglio","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jsat.2011.09.007_bb0185","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2036.2004.01906.x","article-title":"Review article: Hepatitis vaccination in patients with chronic liver disease","volume":"19","author":"Reiss","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.jsat.2011.09.007_bb0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2006-947298","article-title":"Viral hepatitis and liver transplantation","volume":"26","author":"Sharma","year":"2006","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.jsat.2011.09.007_bb0195","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.jsat.2011.09.007_bb0200","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602333","article-title":"A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China","volume":"92","author":"Shi","year":"2005","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jsat.2011.09.007_bb0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0376-8716(99)00104-0","article-title":"Drug abuse treatment as an HIV prevention strategy: A review","volume":"59","author":"Sorensen","year":"2000","journal-title":"Drug & Alcohol Dependence"},{"key":"10.1016\/j.jsat.2011.09.007_bb0210","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jhep.2005.06.012","article-title":"An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users","volume":"43","author":"Spada","year":"2005","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0215","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2011.09.007_bb0220","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.drugalcdep.2003.08.009","article-title":"A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States","volume":"73","author":"Strauss","year":"2004","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2011.09.007_bb0225","series-title":"Results from the 2004 National Survey on Drug Use and Health: National Findings (Office of Applied Studies), NSDUH Series H-28. DHHS Publication No. SMA 05-4062","author":"Substance Abuse & Mental Health Services Administration","year":"2005"},{"key":"10.1016\/j.jsat.2011.09.007_bb0230","series-title":"National Survey of Substance Abuse Treatment Programs (N-SSATS): 2004. Data on Substance Abuse Treatment Facilities, DASIS Series: S-28. DHHS Publication No. SMA 05-4112","author":"Substance Abuse & Mental Health Services Administration","year":"2005"},{"issue":"Suppl 5","key":"10.1016\/j.jsat.2011.09.007_bb0235","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1086\/427440","article-title":"Epidemiology and natural history of hepatitis C virus infection in injection drug users: Implications for treatment","volume":"40","author":"Sulkowski","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2011.09.007_bb0240","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1081\/JA-100102640","article-title":"Hepatitis C among noninjecting drug users: A report","volume":"36","author":"Tortu","year":"2001","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2011.09.007_bb0245","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1081\/JA-120028488","article-title":"Sharing of noninjection drug-use implements as a risk factor for hepatitis C","volume":"39","author":"Tortu","year":"2004","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2011.09.007_bb0250","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJM199801293380503","article-title":"Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C","volume":"338","author":"Vento","year":"1998","journal-title":"New England Journal of Medicine"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547211001772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547211001772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:37:30Z","timestamp":1760038650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547211001772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0740547211001772"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2011.09.007","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2011.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}